Last reviewed · How we verify
Escherichia coli ESBL
This appears to be a therapeutic intervention targeting extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli infections.
This appears to be a therapeutic intervention targeting extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli infections. Used for Infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
At a glance
| Generic name | Escherichia coli ESBL |
|---|---|
| Sponsor | José Raimundo Araujo de Azevedo |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
ESBL-producing E. coli are bacteria resistant to many beta-lactam antibiotics. The mechanism likely involves either direct antimicrobial activity against these resistant strains or immunological approaches to enhance clearance of ESBL-producing pathogens. Given the phase 2 status and unconventional designation, this may represent a novel therapeutic modality such as a vaccine, bacteriophage therapy, or immunobiological agent rather than a traditional small-molecule antibiotic.
Approved indications
- Infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli
Common side effects
Key clinical trials
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Cefotetan Therapy for Escherichia Coli Infections (PHASE2)
- Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli
- Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli
- Comparison of Pulsed-field Gel Electrophoresis and Whole Genome Sequencing to Determine Transmission Rate of ESBL-producing E.Coli
- Antimicrobial Resistance in Hospitals From Meta, Colombia
- Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae (PHASE4)
- Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escherichia coli ESBL CI brief — competitive landscape report
- Escherichia coli ESBL updates RSS · CI watch RSS
- José Raimundo Araujo de Azevedo portfolio CI